Fischer S, Tandstad T, Cohn-Cedermark G, et al. - By performing this retrospective analysis, researchers determined the outcomes of patients (n = 51) with clinical stage I nonseminoma (NS) who experienced a relapse following adjuvant bleomycin, etoposide, and cisplatin (BEP). The data from these patients were obtained from 18 centers/11 countries and analyzed for overall survival and progression-free survival estimated from day 1 of treatment at first relapse. The focus was also laid on time to, stage at, and treatment of relapse and rate of subsequent relapses (secondary outcomes). Findings are suggestive of better outcomes of patients with relapse post-adjuvant BEP vs those who had a relapse following treatment of metastatic disease, though worse outcomes were noted when compared with those who had de-novo metastatic disease. Also, the observed rate of late and subsequent relapses was substantial. Three patterns of relapse with distinct outcomes were noted : pure teratoma, early viable NS relapse (< 2 years), and late viable NS relapse (> 2 years).